Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy | Abstract

Asploro Journal of Biomedical and Clinical Case Reports

Asploro Journal of Biomedical and Clinical Case Reports

ISSN: 2582-0370

Article Type: Case Report

DOI: 10.36502/2023/ASJBCCR.6293

Asp Biomed Clin Case Rep. 2023 Apr 14;6(2):69-75

Hiroshi BANDO1,2iD*, Hisako YAMASHITA2, Yoshinobu KATO2, Katsunori OGURA2, Yoshikane KATO2
1Tokushima University/Medical research, Tokushima, Japan
2Kanaiso Hospital, Komatsushima, Tokushima, Japan

Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ORCID iD
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 15 March 2023; Accepted date: 10 April 2023; Published date: 14 April 2023

Citation: Bando H, Yamashita H, Kato Y, Ogura K, Kato Y. Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy. Asp Biomed Clin Case Rep. 2023 Apr 14;6(2):69-75.

Copyright © 2023 Bando H, Yamashita H, Kato Y, Ogura K, Kato Y. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Vildagliptin / Metformin (Equmet), Imeglimin (Twymeeg), Gastro-Intestinal Adverse Effects, Trials of Imeglimin for Efficacy and Safety, Vildagliptin Efficacy in Combination with Metformin for Early Treatment of Type 2 Diabetes

Abbreviations: GIAEs: Gastro-Intestinal Adverse Effects; TIMES: Trials of Imeglimin for Efficacy and Safety; VERIFY: Vildagliptin Efficacy in combination with metfoRmIn For earlY Treatment of Type 2 Diabetes

Abstract

Background: Vildagliptin/Metformin (EquMet) and imeglimin (Twymeeg) are effective oral hypoglycemic agents (OHAs) for patients with type 2 diabetes (T2D).
Case Presentation: The patient was a 68-year-old male with T2D and fatty liver for several years. In November 2022, his HbA1c had increased to 8.2%, and he was started on Twymeeg, followed by EquMet.
Results: Over the course of four months, the patient’s HbA1c value successfully decreased from 8.2% to 6.7%, and he did not experience any gastrointestinal adverse effects (GIAEs).
Discussion and Conclusion: The combined treatment of EquMet and Twymeeg demonstrated clinical efficacy without any adverse effects. The Trials of IMeglimin for Efficacy and Safety (TIMES) provided various evidence of imeglimin’s effectiveness.

Facebooktwitterlinkedininstagramflickrfoursquaremail

asploro

Asploro Open Access Publications Limited